Demant A/S (WILYY)
NEUTRALFundamental
49
मूल्य
$823.00
मार्केट कैप
$33.77B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Demant is a Danish hearing healthcare group that designs and manufactures hearing aids sold under brands including Oticon and Bernafon, and runs a network of owned and franchised clinics where audiologists test patients' hearing and fit them with a device. A smaller unit sells diagnostic equipment, such as audiometers and balance-testing systems, to clinics and hospitals. It sold a separate communications business, which made headsets and speakerphones, and has treated it as a discontinued operation since 2024.
यह पैसा कैसे कमाती है
Most revenue comes from selling hearing aids, physical devices fitted to a patient's ear that are typically replaced every several years, plus recurring sales of batteries, accessories, repairs and clinical services around them. A smaller stream comes from selling diagnostic equipment to clinics and hospitals. Because hearing loss is a chronic, progressive condition, each patient tends to return to buy a replacement device or accessories over time, and purchases are often reimbursed or subsidized by public healthcare systems in Demant's main markets.
मांग को क्या चलाता है
डिफेंसिवHearing loss is mainly a consequence of aging, so the number of people who need a hearing aid grows steadily with an older population and is not closely tied to how the economy is doing in a given year. Purchases can still be postponed for a few months by a household under financial strain, but the underlying medical need does not disappear the way demand for a discretionary product would in a downturn.
खरीदने के पक्ष में तर्क
Buyers argue that an aging population in Demant's main markets keeps the number of potential hearing aid users growing for decades to come, and that 2025's revenue growth shows the underlying demand for its devices and clinics remaining solid.
बेचने के पक्ष में तर्क
Sellers worry that 2025's profit fell even as revenue grew, forcing the company into a cost-cutting programme, and that pricing and reimbursement pressure in a market with several well-capitalized rivals could keep squeezing margins even if the number of patients keeps rising.
Written by the editors, published on 18 अगस्त 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$3.48B
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
शुद्ध आय
$234M
अंतिम प्रकाशित तिमाही तक के पिछले 12 महीने — प्रति शेयर मेट्रिक्स से अनुमानित
Free Cash Flow
-
कुल इक्विटी
$24.56B
कुल देनदारियाँ
$426M
Current Ratio
1.63
Interest Coverage
-
Debt/EBITDA
2.60
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$1931.85
वर्तमान मूल्य
$823.00
Margin of Safety
+57.4%
Fair Value सीमा
$1255.70 - $2608.00
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
111.11
ROE
2.7%
P/B Ratio
17.40
P/FCF
-
Gross Margin
75.6%
ROIC
0.5%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
0.5%
WACC
7.9%
ROIC − WACC
-7.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (10)
- Price CAGR 13.59%
- Gross Margin 75.6%
- Debt/Equity ratio
- Operating Margin 16.7%
- Current Ratio
- Debt/EBITDA
- ROE 16.1%
- Revenue Growth 5Y 9.7%
- Analyst Consensus 65% Buy
- Net Margin Trend 53.0% vs 43.8%
फेल (8)
- ROIC 0.5%
- P/B Ratio 17.40
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Surprise avg -11.2%
- PEG Ratio 4.10
- Earnings Quality (OCF/NI) 0.29
- Piotroski F-Score 1/9
अनुपलब्ध (9)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Share Dilution (missing shares data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Mr. Thomas Wilhelmsen | Group Chief Executive Officer | 51 |
| Mr. Christian Berg | Group Chief Financial Officer | 56 |
| Mr. Bjorge Grimholt | Executive Vice President of Maritime Services | - |
| Ms. Benedicte Teigen Gude | Chief of Staff | - |
| Mr. Geir Flaesen | Executive Vice President of New Energy | - |
| Mr. Carl Schou | President & CEO of Wilhelmsen Ship Management (WSM) | - |
| Mr. John Egil Stangeland | Chief Executive Officer of NorSea Group | - |
| Mr. Age Sturtzel Holm | Vice President of Investor Relations & Corporate Support | - |
| Ms. Anna Kverneland | Vice President of Investor Relations | - |
Audit जोखिम
2
बोर्ड जोखिम
4
मुआवजा जोखिम
6
शेयरधारक अधिकार जोखिम
9
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for WILYY, sourced from Markets Gazette.